The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinsons Disease and/or complications associated with Parkinsons Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinsons Disease in an at-risk patient and/or treat or prevent the onset of Parkinsons Disease-associated symptoms.
